Literature DB >> 27123760

On confidence intervals for the hazard ratio in randomized clinical trials.

Dan-Yu Lin1, Luyan Dai2, Gang Cheng2, Martin Oliver Sailer3.   

Abstract

The log-rank test is widely used to compare two survival distributions in a randomized clinical trial, while partial likelihood (Cox, 1975) is the method of choice for making inference about the hazard ratio under the Cox (1972) proportional hazards model. The Wald 95% confidence interval of the hazard ratio may include the null value of 1 when the p-value of the log-rank test is less than 0.05. Peto et al. (1977) provided an estimator for the hazard ratio based on the log-rank statistic; the corresponding 95% confidence interval excludes the null value of 1 if and only if the p-value of the log-rank test is less than 0.05. However, Peto's estimator is not consistent, and the corresponding confidence interval does not have correct coverage probability. In this article, we construct the confidence interval by inverting the score test under the (possibly stratified) Cox model, and we modify the variance estimator such that the resulting score test for the null hypothesis of no treatment difference is identical to the log-rank test in the possible presence of ties. Like Peto's method, the proposed confidence interval excludes the null value if and only if the log-rank test is significant. Unlike Peto's method, however, this interval has correct coverage probability. An added benefit of the proposed confidence interval is that it tends to be more accurate and narrower than the Wald confidence interval. We demonstrate the advantages of the proposed method through extensive simulation studies and a colon cancer study.
© 2016, The International Biometric Society.

Entities:  

Keywords:  Censoring; Cox model; Log-rank test; Partial likelihood; Peto's method; Proportional hazards; Score test

Mesh:

Year:  2016        PMID: 27123760      PMCID: PMC5085885          DOI: 10.1111/biom.12528

Source DB:  PubMed          Journal:  Biometrics        ISSN: 0006-341X            Impact factor:   2.571


  6 in total

1.  A comparison of two simple hazard ratio estimators based on the logrank test.

Authors:  G Berry; R M Kitchin; P A Mock
Journal:  Stat Med       Date:  1991-05       Impact factor: 2.373

2.  Covariance analysis of censored survival data.

Authors:  N Breslow
Journal:  Biometrics       Date:  1974-03       Impact factor: 2.571

3.  Beta blockade during and after myocardial infarction: an overview of the randomized trials.

Authors:  S Yusuf; R Peto; J Lewis; R Collins; P Sleight
Journal:  Prog Cardiovasc Dis       Date:  1985 Mar-Apr       Impact factor: 8.194

4.  Evaluation of survival data and two new rank order statistics arising in its consideration.

Authors:  N Mantel
Journal:  Cancer Chemother Rep       Date:  1966-03

5.  Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma.

Authors:  C G Moertel; T R Fleming; J S Macdonald; D G Haller; J A Laurie; P J Goodman; J S Ungerleider; W A Emerson; D C Tormey; J H Glick
Journal:  N Engl J Med       Date:  1990-02-08       Impact factor: 91.245

6.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples.

Authors:  R Peto; M C Pike; P Armitage; N E Breslow; D R Cox; S V Howard; N Mantel; K McPherson; J Peto; P G Smith
Journal:  Br J Cancer       Date:  1977-01       Impact factor: 7.640

  6 in total
  6 in total

1.  Vaccine-mediated protection against Campylobacter-associated enteric disease.

Authors:  Benjamin K Quintel; Kamm Prongay; Anne D Lewis; Hans-Peter Raué; Sara Hendrickson; Nicholas S Rhoades; Ilhem Messaoudi; Lina Gao; Mark K Slifka; Ian J Amanna
Journal:  Sci Adv       Date:  2020-06-24       Impact factor: 14.136

2.  Association of Titin-Truncating Genetic Variants With Life-threatening Cardiac Arrhythmias in Patients With Dilated Cardiomyopathy and Implanted Defibrillators.

Authors:  Ben Corden; Julian Jarman; Nicola Whiffin; Upasana Tayal; Rachel Buchan; Joban Sehmi; Andrew Harper; William Midwinter; Karen Lascelles; Vias Markides; Mark Mason; John Baksi; Antonis Pantazis; Dudley J Pennell; Paul J Barton; Sanjay K Prasad; Tom Wong; Stuart A Cook; James S Ware
Journal:  JAMA Netw Open       Date:  2019-06-05

3.  Restart of Anticoagulant Therapy and Risk of Thrombosis, Rebleeding, and Death after Factor Xa Inhibitor Reversal in Major Bleeding Patients.

Authors:  Truman J Milling; Ben King; Patrick Yue; Saskia Middeldorp; Jan Beyer-Westendorf; John W Eikelboom; Mark Crowther; Lizhen Xu; Peter Verhamme; Deborah M Siegal; Stuart J Connolly
Journal:  Thromb Haemost       Date:  2021-04-14       Impact factor: 6.681

4.  Effects of canagliflozin on initiation of insulin and other antihyperglycaemic agents in the CANVAS Program.

Authors:  David R Matthews; Carol Wysham; Melanie Davies; April Slee; Maria Alba; Mary Lee; Vlado Perkovic; Kenneth W Mahaffey; Bruce Neal
Journal:  Diabetes Obes Metab       Date:  2020-08-24       Impact factor: 6.577

5.  Vaccine Effectiveness Following Routine Immunization With Bivalent Human Papillomavirus (HPV) Vaccine: Protection Against Incident Genital HPV Infections From a Reduced-Dosing Schedule.

Authors:  Joske Hoes; Audrey J King; Tessa M Schurink Van't Klooster; Johannes Berkhof; Johannes A Bogaards; Hester E de Melker
Journal:  J Infect Dis       Date:  2022-09-04       Impact factor: 7.759

6.  The Impact of the Underlying Risk in Control Group and Effect Measures in Non-Inferiority Trials With Time-to-Event Data: A Simulation Study.

Authors:  Xuanqian Xie; Chenglin Ye; Nicholas Mitsakakis
Journal:  J Clin Med Res       Date:  2018-03-16
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.